Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Short-term Investments (2022 - 2025)

Summit Therapeutics (SMMT) has disclosed Short-term Investments for 4 consecutive years, with $149.8 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Short-term Investments rose 47152.05% year-over-year to $149.8 million, compared with a TTM value of $149.8 million through Mar 2025, up 47152.05%, and an annual FY2024 reading of $307.5 million, changed N/A over the prior year.
  • Short-term Investments was $149.8 million for Q1 2025 at Summit Therapeutics, down from $307.5 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $307.5 million in Q4 2024 and bottomed at $317000.0 in Q1 2024.
  • Average Short-term Investments over 4 years is $133.0 million, with a median of $149.8 million recorded in 2025.
  • The sharpest move saw Short-term Investments plummeted 99.81% in 2024, then surged 47152.05% in 2025.
  • Year by year, Short-term Investments stood at $300.0 million in 2022, then plummeted by 42.37% to $172.9 million in 2023, then skyrocketed by 77.84% to $307.5 million in 2024, then tumbled by 51.29% to $149.8 million in 2025.
  • Business Quant data shows Short-term Investments for SMMT at $149.8 million in Q1 2025, $307.5 million in Q4 2024, and $323000.0 in Q3 2024.